Semiparametric estimation of the cure fraction in population‐based cancer survival analysis
Gu, Ennan, Zhang, Jiajia, Lu, Wenbin, Wang, Lianming, Felizzi, Federico
Published in Statistics in medicine (20.11.2020)
Published in Statistics in medicine (20.11.2020)
Get full text
Journal Article
CML-573 ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Atallah, Ehab, Mauro, Michael, Sasaki, Koji, Levy, Moshe, Koller, Paul, Yang, Daisy, Laine, Dramane, Sabo, John, Gu, Ennan, Cortes, Jorge
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
POSTER: CML-573 ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Atallah, Ehab, Mauro, Michael, Sasaki, Koji, Levy, Moshe, Koller, Paul, Yang, Daisy, Laine, Dramane, Sabo, John, Gu, Ennan, Cortes, Jorge
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA -mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study
Juric, Dejan, Rugo, Hope S., Chia, Stephen K.L., Lerebours, Florence, Ruiz-Borrego, Manuel, Drullinsky, Pamela, Ciruelos, Eva M., Neven, Patrick, Park, Yeon Hee, Arce, Christina H., Gu, Ennan, Joshi, Mukta, Roux, Estelle, Akdere, Murat, Turner, Nicholas C.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A
Ciruelos, Eva M, Lerebours, Florence, Rugo, Hope S, Ruiz-Borrego, Manuel, Drullinsky, Pamela, Prat, Aleix, Bachelot, Thomas, Neven, Patrick, Park, Yeon Hee, Turner, Nicholas, Juric, Dejan, Gu, Ennan, Arce, Christina H, Akdere, Murat, Chia, Stephen
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated advanced breast cancer (ABC) from BYLieve
Chia, Stephen, Ciruelos, Eva M, Rugo, Hope S, Lerebours, Florence, Ruiz-Borrego, Manuel, Drullinsky, Pamela, Prat, Aleix, Bachelot, Thomas, Turner, Nicholas, Gu, Ennan, Arce, Christina, Akdere, Murat, Juric, Dejan
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA -mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses
Rugo, Hope S, Neven, Patrick, Saffie, Isabel, Park, Yeon Hee, De Laurentiis, Michelino, Lerebours, Florence, Ciruelos, Eva Maria, Turner, Nicholas, Juric, Dejan, Gu, Ennan, Arce, Christina H, Joshi, Mukta, Roux, Estelle, Akdere, Murat, Chia, Stephen
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial
Atallah, Ehab L, Mauro, Michael J, Sasaki, Koji, Levy, Moshe Y, Koller, Paul, Yang, Daisy, Laine, Dramane, Sabo, John, Gu, Ennan, Cortes, Jorge E
Published in Future oncology (London, England) (10.10.2024)
Published in Future oncology (London, England) (10.10.2024)
Get more information
Journal Article
Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA -mutated advanced breast cancer (ABC) from BYLieve
Chia, Stephen K. L., Ruiz-Borrego, Manuel, Drullinsky, Pamela, Juric, Dejan, Bachelot, Thomas, Rugo, Hope S., Ciruelos, Eva M., Lerebours, Florence, Prat, Aleix, Akdere, Murat, Arce, Christina, Gu, Ennan, Turner, Nicholas C.
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
CML-345 Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Issa, Ghayas C., Larson, Richard A., Hughes, Timothy P., Hochhaus, Andreas, Takahashi, Naoto, Bombaci, Felice, Wang, Jianxiang, Kim, Dong-Wook, Dong Hwan Kim, Dennis, Gu, Ennan, Zhang, Yifan, Kapoor, Shruti, Agrawal, Nithya, Jinwal, Rajendra, Damon, Andrea, Sadek, Islam, Cortes, Jorge E.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Issa, Ghayas C., Larson, Richard A., Hughes, Timothy P., Hochhaus, Andreas, Takahashi, Naoto, Bombaci, Felice, Wang, Jianxiang, Kim, Dong-Wook, Dong Hwan Kim, Dennis, Gu, Ennan, Zhang, Yifan, Kapoor, Shruti, Agrawal, Nithya, Jinwal, Rajendra, Damon, Andrea, Sadek, Islam, Cortes, Jorge E.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
Estimation on conditional restricted mean survival time with counting process
Qiu, Junshan, Gu, Ennan, Zhou, Dali, Lawrence, John, Bai, Steven, Hung, Hsien Ming J.
Published in Journal of biopharmaceutical statistics (03.09.2019)
Published in Journal of biopharmaceutical statistics (03.09.2019)
Get full text
Journal Article
ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment
Atallah, Ehab L., Mauro, Michael, Sasaki, Koji, Levy, Moshe, Koller, Paul B., Yang, Daisy, Laine, Dramane, Sabo, John, GU, Ennan, Cortes, Jorge
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article